In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Evotec Drug Development Strategy Offers Little Downside, Big Upside

Executive Summary

Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.


Related Content

Verseon Claims Major Move In Drug Design, Will Enter Clinic Within A Year
Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal
Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals
Evotec Says DiaPep Demise Delays Goals, Spotlight Now On Roche Pact
Evotec Buys Bionamics For Shortcut To German Academic Gems
MorphoSys: Accelerating The Long Transformation
Deals Of The Week: Shire/arGEN-X/Ethris, Evotec/Yale, Amgen/Bind Biosciences
A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
Roche Takes Back Evotec's EVT-302 To Develop In Alzheimer's Disease, In $800 Million Deal
Evotec's Restructuring Leads To Q1 Improved Revenues and Reduced Losses


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts